<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33011853</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1459</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>268</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurology</Title>
          <ISOAbbreviation>J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.</ArticleTitle>
        <Pagination>
          <StartPage>4522</StartPage>
          <EndPage>4536</EndPage>
          <MedlinePgn>4522-4536</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-020-10235-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Treatment of neuromyelitis optica spectrum disorder (NMOSD) has so far been based on retrospective case series. The results of six randomized clinical trials including five different monoclonal antibodies targeting four molecules and three distinct pathophysiological pathways have recently been published.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Literature search on clinical trials and case studies in NMOSD up to July 10. 2020.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We review mechanism of action, efficacy and side effects, and consequences for reproductive health from traditional immunosuppressants and monoclonal antibodies including rituximab, inebilizumab, eculizumab, tocilizumab and satralizumab.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In NMOSD patients with antibodies against aquaporin 4, monoclonal antibodies that deplete B cells (rituximab and inebilizumab) or interfere with interleukin 6 signaling (tocilizumab and satralizumab) or complement activation (eculizumab) have superior efficacy compared to placebo. Tocilizumab and rituximab were also superior to azathioprine in head-to-head studies. Rituximab, tocilizumab and to some extent eculizumab have well-known safety profiles for other inflammatory diseases, and rituximab and azathioprine may be safe during pregnancy.</AbstractText>
          <CopyrightInformation>© 2020. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Holmøy</LastName>
            <ForeName>Trygve</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-2529-5664</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Akershus University Hospital, Lørenskog, Norway. Trygve.holmoy@medisin.uio.no.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Trygve.holmoy@medisin.uio.no.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Høglund</LastName>
            <ForeName>Rune Alexander</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Akershus University Hospital, Lørenskog, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Illes</LastName>
            <ForeName>Zsolt</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Odense University Hospital, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Myhr</LastName>
            <ForeName>Kjell-Morten</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Bergen, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Torkildsen</LastName>
            <ForeName>Øivind</ForeName>
            <Initials>Ø</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Bergen, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neurol</MedlineTA>
        <NlmUniqueID>0423161</NlmUniqueID>
        <ISSNLinking>0340-5354</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4F4X42SYQ6</RegistryNumber>
          <NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YB18NF020M</RegistryNumber>
          <NameOfSubstance UI="C000655944">satralizumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="Y">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Demyelinating diseases</Keyword>
        <Keyword MajorTopicYN="N">Monoclonal antibodies</Keyword>
        <Keyword MajorTopicYN="N">Neuromyelitis optica spectrum disorder</Keyword>
        <Keyword MajorTopicYN="N">Treatment</Keyword>
      </KeywordList>
      <CoiStatement>Trygve Holmøy has received speakers’ honoraria and/or unrestricted research grants from Biogen, Roche, Sanofi and Merck, and has been principal investigator in studies sponsored by Biogen, Merck and Roche. Rune A. Høglund has received speakers’ honoraria and/or unrestricted grants from Biogen, Merck, Roche and Novartis, and participated as investigator in study sponsored by Roche. Zsolt Illes has received speakers’ honoraria and/or research grants from Biogen, Roche, Sanofi, Novartis and Merck, has been member of advisory boards at Alexion, Biogen, Sanofi, Merck, Roche, Novartis, was member of the adjudication relapse committee in the SAkuraStar and SAkuraSky trials, and has been principal investigator in studies sponsored by Biogen, Merck and Sanofi. Øivind Torkildsen has received speakers’ honoraria and/or unrestricted research grants from Biogen, Roche, Novartis, Merck and Sanofi and has been principal investigator in studies sponsored by Sanofi. Kjell-Morten Myhr has received unrestricted research grants to his institution; scientific advisory board, and speakers’ honoraria from Almirall, Biogen, Genzyme, Merck, Novartis, Roche, or Teva; and has participated in clinical trials organized by Biogen, Merck, Novartis, or Roche.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>4</Day>
          <Hour>20</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33011853</ArticleId>
        <ArticleId IdType="pmc">PMC8563615</ArticleId>
        <ArticleId IdType="doi">10.1007/s00415-020-10235-5</ArticleId>
        <ArticleId IdType="pii">10.1007/s00415-020-10235-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805–815. doi: 10.1016/S1474-4422(07)70216-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(07)70216-8</ArticleId>
            <ArticleId IdType="pubmed">17706564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189. doi: 10.1212/WNL.0000000000001729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001729</ArticleId>
            <ArticleId IdType="pmc">PMC4515040</ArticleId>
            <ArticleId IdType="pubmed">26092914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mader S, Kumpfel T, Meinl E. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases. Curr Opin Neurol. 2020;33(3):362–371. doi: 10.1097/WCO.0000000000000813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0000000000000813</ArticleId>
            <ArticleId IdType="pubmed">32304439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, et al.  Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. 2020;143(5):1431–1446. doi: 10.1093/brain/awaa102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awaa102</ArticleId>
            <ArticleId IdType="pubmed">32412053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, et al.  Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol. 2018;75(11):1355–1363. doi: 10.1001/jamaneurol.2018.1814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2018.1814</ArticleId>
            <ArticleId IdType="pmc">PMC6248120</ArticleId>
            <ArticleId IdType="pubmed">30014148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al.  Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflamm. 2012;2012(9):14. doi: 10.1186/1742-2094-9-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1742-2094-9-14</ArticleId>
            <ArticleId IdType="pmc">PMC3283476</ArticleId>
            <ArticleId IdType="pubmed">22260418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler. 2012;18(10):1480–1483. doi: 10.1177/1352458512439439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458512439439</ArticleId>
            <ArticleId IdType="pubmed">22354738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol. 2016;263(1):25–29. doi: 10.1007/s00415-015-7925-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-015-7925-y</ArticleId>
            <ArticleId IdType="pubmed">26477020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitley J, Evangelou N, Kuker W, Jacob A, Leite MI, Palace J. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J Neurol Sci. 2014;339(1–2):223–225. doi: 10.1016/j.jns.2014.01.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2014.01.035</ArticleId>
            <ArticleId IdType="pubmed">24576801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duchow A, Paul F, Bellmann-Strobl J. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. Expert Opin Biol Ther. 2020;13:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32228250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et al.  Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298–306. doi: 10.1016/S1474-4422(20)30066-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30066-1</ArticleId>
            <ArticleId IdType="pubmed">32199095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al.  Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–1363. doi: 10.1016/S0140-6736(19)31817-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(19)31817-3</ArticleId>
            <ArticleId IdType="pubmed">31495497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al.  Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402–412. doi: 10.1016/S1474-4422(20)30078-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30078-8</ArticleId>
            <ArticleId IdType="pmc">PMC7935419</ArticleId>
            <ArticleId IdType="pubmed">32333898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al.  Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114–2124. doi: 10.1056/NEJMoa1901747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1901747</ArticleId>
            <ArticleId IdType="pubmed">31774956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al.  Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–625. doi: 10.1056/NEJMoa1900866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1900866</ArticleId>
            <ArticleId IdType="pubmed">31050279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, et al.  Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391–401. doi: 10.1016/S1474-4422(20)30070-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30070-3</ArticleId>
            <ArticleId IdType="pmc">PMC7935423</ArticleId>
            <ArticleId IdType="pubmed">32333897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tradtrantip L, Asavapanumas N, Verkman AS. Emerging therapeutic targets for neuromyelitis optica spectrum disorder. Expert Opin Ther Targets. 2020;24(3):219–229. doi: 10.1080/14728222.2020.1732927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14728222.2020.1732927</ArticleId>
            <ArticleId IdType="pmc">PMC7941255</ArticleId>
            <ArticleId IdType="pubmed">32070155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim W, Kim SH, Nakashima I, Takai Y, Fujihara K, Leite MI, et al.  Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012;78(16):1264–1267. doi: 10.1212/WNL.0b013e318250d812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e318250d812</ArticleId>
            <ArticleId IdType="pubmed">22491862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nour MM, Nakashima I, Coutinho E, Woodhall M, Sousa F, Revis J, et al.  Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology. 2016;86(1):79–87. doi: 10.1212/WNL.0000000000002208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002208</ArticleId>
            <ArticleId IdType="pmc">PMC4731292</ArticleId>
            <ArticleId IdType="pubmed">26581304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delgado-Garcia G, Chavez Z, Rivas-Alonso V, Corona T, Flores-Rivera J. Obstetric outcomes in a Mexican cohort of patients with AQP4-antibody-seropositive neuromyelitis optica. Mult Scler Relat Disord. 2018;25:268–270. doi: 10.1016/j.msard.2018.08.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2018.08.015</ArticleId>
            <ArticleId IdType="pubmed">30149303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, et al.  High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017;89(22):2238–2244. doi: 10.1212/WNL.0000000000004681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000004681</ArticleId>
            <ArticleId IdType="pmc">PMC5705247</ArticleId>
            <ArticleId IdType="pubmed">29093070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao-Draayer Y, Thiel S, Mills EA, Chitnis T, Fabian M, Katz SI, et al.  Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020;16(3):154–170. doi: 10.1038/s41582-020-0313-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-020-0313-y</ArticleId>
            <ArticleId IdType="pubmed">32080393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shosha E, Pittock SJ, Flanagan E, Weinshenker BG. Neuromyelitis optica spectrum disorders and pregnancy: interactions and management. Mult Scler. 2017;23(14):1808–1817. doi: 10.1177/1352458517740215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458517740215</ArticleId>
            <ArticleId IdType="pubmed">29154728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borisow N, Hellwig K, Paul F. Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies. EPMA J. 2018;9(3):249–256. doi: 10.1007/s13167-018-0143-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13167-018-0143-9</ArticleId>
            <ArticleId IdType="pmc">PMC6107451</ArticleId>
            <ArticleId IdType="pubmed">30174761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragoso YD, Sousa NAC, Alves-Leon SV, Dias RM, Pimentel MLV, Gomes S, et al.  Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD) Mult Scler Relat Disord. 2019;27:392–396. doi: 10.1016/j.msard.2018.11.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2018.11.031</ArticleId>
            <ArticleId IdType="pubmed">30504040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, et al.  Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007;13(8):968–974. doi: 10.1177/1352458507077189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458507077189</ArticleId>
            <ArticleId IdType="pubmed">17623727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al.  CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Investig. 2003;111(8):1133–1145. doi: 10.1172/JCI16432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI16432</ArticleId>
            <ArticleId IdType="pmc">PMC152932</ArticleId>
            <ArticleId IdType="pubmed">12697733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51(4):1219–1220. doi: 10.1212/WNL.51.4.1219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.51.4.1219</ArticleId>
            <ArticleId IdType="pubmed">9781568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, et al.  Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77(7):659–666. doi: 10.1212/WNL.0b013e31822a2780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31822a2780</ArticleId>
            <ArticleId IdType="pubmed">21813788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324–330. doi: 10.1001/jamaneurol.2013.5699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2013.5699</ArticleId>
            <ArticleId IdType="pubmed">24445513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, de Amorin SN, Gabbai AA. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol. 2010;67(9):1131–1136. doi: 10.1001/archneurol.2010.203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2010.203</ArticleId>
            <ArticleId IdType="pubmed">20837859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bichuetti DB, Perin MMM, Souza NA, Oliveira EML. Treating neuromyelitis optica with azathioprine: 20-year clinical practice. Mult Scler. 2019;25(8):1150–1161. doi: 10.1177/1352458518776584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458518776584</ArticleId>
            <ArticleId IdType="pubmed">29761736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahraian MA, Moinfar Z, Khorramnia S, Ebrahim MM. Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur J Neurol. 2010;17(6):794–799. doi: 10.1111/j.1468-1331.2009.02928.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2009.02928.x</ArticleId>
            <ArticleId IdType="pubmed">20100229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S, et al.  Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014;20(11):1533–1540. doi: 10.1177/1352458514525870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458514525870</ArticleId>
            <ArticleId IdType="pubmed">24647557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torres J, Pruitt A, Balcer L, Galetta S, Markowitz C, Dahodwala N. Analysis of the treatment of neuromyelitis optica. J Neurol Sci. 2015;351(1–2):31–35. doi: 10.1016/j.jns.2015.02.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2015.02.012</ArticleId>
            <ArticleId IdType="pubmed">25727350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler. 2016;22(3):329–339. doi: 10.1177/1352458515587752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458515587752</ArticleId>
            <ArticleId IdType="pubmed">26041804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang W, Wang L, Zhang B, Zhou L, Zhang T, Quan C. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis. Mult Scler Relat Disord. 2019;35:246–252. doi: 10.1016/j.msard.2019.08.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2019.08.009</ArticleId>
            <ArticleId IdType="pubmed">31425902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264(9):2003–2009. doi: 10.1007/s00415-017-8590-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-017-8590-0</ArticleId>
            <ArticleId IdType="pubmed">28831548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol. 1973;115(8):1100–1106. doi: 10.1016/0002-9378(73)90559-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0002-9378(73)90559-0</ArticleId>
            <ArticleId IdType="pubmed">4348000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Boer NK, Jarbandhan SV, Mulder CJ, van Elburg RM, van Bodegraven AA. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol. 2006;101(6):1390–1392. doi: 10.1111/j.1572-0241.2006.00538.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1572-0241.2006.00538.x</ArticleId>
            <ArticleId IdType="pubmed">16771965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, et al.  Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79(10):696–701. doi: 10.1002/bdra.20399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bdra.20399</ArticleId>
            <ArticleId IdType="pubmed">17847119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol. 2009;85(7):647–654. doi: 10.1002/bdra.20583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bdra.20583</ArticleId>
            <ArticleId IdType="pubmed">19343728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124(1):9–17. doi: 10.1053/gast.2003.50014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/gast.2003.50014</ArticleId>
            <ArticleId IdType="pubmed">12512024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, et al.  Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014;63(3):451–457. doi: 10.1136/gutjnl-2012-303615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2012-303615</ArticleId>
            <ArticleId IdType="pubmed">23424097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K. Azathioprine treatment during lactation. Aliment Pharmacol Ther. 2008;28(10):1209–1213. doi: 10.1111/j.1365-2036.2008.03843.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2036.2008.03843.x</ArticleId>
            <ArticleId IdType="pubmed">18761704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sau A, Clarke S, Bass J, Kaiser A, Marinaki A, Nelson-Piercy C. Azathioprine and breastfeeding: is it safe? BJOG. 2007;114(4):498–501. doi: 10.1111/j.1471-0528.2006.01232.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-0528.2006.01232.x</ArticleId>
            <ArticleId IdType="pubmed">17261122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institute of health. Azathioprine. Drugs and lactation Database (lactMed). https://www.ncbi.nlm.nih.gov/books/NBK501050/. Accessed 20 Apr 2020</Citation>
        </Reference>
        <Reference>
          <Citation>Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol. 1993;14(4):353–380. doi: 10.1007/BF00192309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00192309</ArticleId>
            <ArticleId IdType="pubmed">8322167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Falcini F, Trapani S, Ricci L, Resti M, Simonini G, de Martino M. Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment. Rheumatology (Oxford) 2006;45(7):913–915. doi: 10.1093/rheumatology/kei263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kei263</ArticleId>
            <ArticleId IdType="pubmed">16638802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al.  Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2016;66(9):1128–1133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19752302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Zhang Y, Shi Z, Feng H, Yao S, Xie J, et al.  The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in western China. Clin Neuropharmacol. 2016;39(2):81–87. doi: 10.1097/WNF.0000000000000131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WNF.0000000000000131</ArticleId>
            <ArticleId IdType="pubmed">26818042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, et al.  Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2014;84(8):918–921. doi: 10.1136/jnnp-2012-304774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2012-304774</ArticleId>
            <ArticleId IdType="pubmed">23467418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramanathan RS, Malhotra K, Scott T. Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol. 2014;15(14):51. doi: 10.1186/1471-2377-14-51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2377-14-51</ArticleId>
            <ArticleId IdType="pmc">PMC3985587</ArticleId>
            <ArticleId IdType="pubmed">24628894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, et al.  Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease) Arch Neurol. 2006;63(7):957–963. doi: 10.1001/archneur.63.7.957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.63.7.957</ArticleId>
            <ArticleId IdType="pubmed">16831964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol. 2011;68(4):473–479. doi: 10.1001/archneurol.2010.322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2010.322</ArticleId>
            <ArticleId IdType="pubmed">21149806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M, et al.  Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med. 2013;52(9):969–972. doi: 10.2169/internalmedicine.52.7885.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.52.7885</ArticleId>
            <ArticleId IdType="pubmed">23648715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Wang Q, Ren HT, Qiao L, Zhang Y, Fei YY, et al.  Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study. J Neurol Sci. 2016;370:224–228. doi: 10.1016/j.jns.2016.09.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2016.09.035</ArticleId>
            <ArticleId IdType="pubmed">27772764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bichuetti DB, Oliveira EM, Boulos FC, Gabbai AA. Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol. 2012;69(7):938–939. doi: 10.1001/archneurol.2012.545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2012.545</ArticleId>
            <ArticleId IdType="pubmed">22777264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kageyama T, Komori M, Miyamoto K, Ozaki A, Suenaga T, Takahashi R, et al.  Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol. 2013;260(2):627–634. doi: 10.1007/s00415-012-6692-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-012-6692-2</ArticleId>
            <ArticleId IdType="pubmed">23076828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyoun SC, Obican SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012;94(4):187–207. doi: 10.1002/bdra.23003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bdra.23003</ArticleId>
            <ArticleId IdType="pubmed">22434686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asgari N, Henriksen TB, Petersen T, Lillevang ST, Weinshenker BG. Pregnancy outcomes in a woman with neuromyelitis optica. Neurology. 2014;83(17):1576–1577. doi: 10.1212/WNL.0000000000000911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000911</ArticleId>
            <ArticleId IdType="pubmed">25239834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet. 2015;4(2):42–55. doi: 10.1055/s-0035-1556743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0035-1556743</ArticleId>
            <ArticleId IdType="pmc">PMC4944211</ArticleId>
            <ArticleId IdType="pubmed">27617117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, et al.  Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party. Mult Scler. 2015;21(2):189–197. doi: 10.1177/1352458514541978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458514541978</ArticleId>
            <ArticleId IdType="pubmed">25078274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aouad P, Li J, Arthur C, Burt R, Fernando S, Parratt J. Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant. J Clin Neurosci. 2015;22(7):1215–1217. doi: 10.1016/j.jocn.2015.02.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2015.02.007</ArticleId>
            <ArticleId IdType="pubmed">25913278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burt RK, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, et al.  Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019;93(18):e1732–e1741. doi: 10.1212/WNL.0000000000008394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000008394</ArticleId>
            <ArticleId IdType="pmc">PMC6946475</ArticleId>
            <ArticleId IdType="pubmed">31578302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uciechowski P, Dempke WCM. Interleukin-6: a masterplayer in the cytokine network. Oncology. 2020;98(3):131–137. doi: 10.1159/000505099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000505099</ArticleId>
            <ArticleId IdType="pubmed">31958792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silver JS, Hunter CA. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol. 2010;88(6):1145–1156. doi: 10.1189/jlb.0410217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.0410217</ArticleId>
            <ArticleId IdType="pmc">PMC2996896</ArticleId>
            <ArticleId IdType="pubmed">20610800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6, designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17(6):395–412. doi: 10.1038/nrd.2018.45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd.2018.45</ArticleId>
            <ArticleId IdType="pubmed">29725131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C, et al.  Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat Immunol. 2017;18(1):74–85. doi: 10.1038/ni.3632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3632</ArticleId>
            <ArticleId IdType="pmc">PMC5164931</ArticleId>
            <ArticleId IdType="pubmed">27893700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, CCree BA, et al.  Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012;72(1):53–64. doi: 10.1002/ana.23651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.23651</ArticleId>
            <ArticleId IdType="pmc">PMC3405197</ArticleId>
            <ArticleId IdType="pubmed">22807325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin J, Li X, Xia J. Th17 cells in neuromyelitis optica spectrum disorder: a review. Int J Neurosci. 2016;126(12):1051–1060. doi: 10.3109/00207454.2016.1163550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/00207454.2016.1163550</ArticleId>
            <ArticleId IdType="pubmed">26954363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uzawa A, Mori M, Ito M, Uchida T, Hayakawa S, Masuda S, et al.  Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol. 2009;256(12):2082–2084. doi: 10.1007/s00415-009-5274-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5274-4</ArticleId>
            <ArticleId IdType="pubmed">19655191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lotan I, McGowan R, Levy M. Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: a systematic review of safety and efficacy. Curr Neuropharmacol. 2020 doi: 10.2174/1570159X18666200429010825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1570159X18666200429010825</ArticleId>
            <ArticleId IdType="pmc">PMC8033980</ArticleId>
            <ArticleId IdType="pubmed">32348222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol. 2011;70(6):943–954. doi: 10.1002/ana.22551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.22551</ArticleId>
            <ArticleId IdType="pmc">PMC3319401</ArticleId>
            <ArticleId IdType="pubmed">22069219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, Yamamoto E, et al.  Effects of neuromyelitis optica-IgG at the blood–brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;4(1):e311. doi: 10.1212/NXI.0000000000000311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000311</ArticleId>
            <ArticleId IdType="pmc">PMC5173350</ArticleId>
            <ArticleId IdType="pubmed">28018943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al.  Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA. 2011;108(9):3701–3706. doi: 10.1073/pnas.1017385108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1017385108</ArticleId>
            <ArticleId IdType="pmc">PMC3048150</ArticleId>
            <ArticleId IdType="pubmed">21321193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosso M, Saxena S, Chitnis T. Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options. Expert Rev Neurother. 2020;20(5):509–516. doi: 10.1080/14737175.2020.1757434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14737175.2020.1757434</ArticleId>
            <ArticleId IdType="pubmed">32306778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araki M. Blockade of IL-6 signaling in neuromyelitis optica. Neurochem Int. 2019;130:104315. doi: 10.1016/j.neuint.2018.10.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2018.10.012</ArticleId>
            <ArticleId IdType="pubmed">30342072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayzenberg I, Kleiter I, Schroder A, Hellwig K, Chan A, Yamamura T, et al.  Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013;70(3):394–397. doi: 10.1001/jamaneurol.2013.1246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2013.1246</ArticleId>
            <ArticleId IdType="pubmed">23358868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kieseier BC, Stuve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, et al.  Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 2013;70(3):390–393. doi: 10.1001/jamaneurol.2013.668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2013.668</ArticleId>
            <ArticleId IdType="pubmed">23599943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, et al.  Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302–1306. doi: 10.1212/WNL.0000000000000317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000317</ArticleId>
            <ArticleId IdType="pmc">PMC4001188</ArticleId>
            <ArticleId IdType="pubmed">24634453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stogbauer F, et al.  Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72(7):756–763. doi: 10.1001/jamaneurol.2015.0533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2015.0533</ArticleId>
            <ArticleId IdType="pubmed">25985228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lotan I, Charlson RW, Ryerson LZ, Levy M, Kister I. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2019 doi: 10.1016/j.msard.2019.101920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2019.101920</ArticleId>
            <ArticleId IdType="pubmed">31918241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choy EH, De BF, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335–345. doi: 10.1038/s41584-020-0419-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41584-020-0419-z</ArticleId>
            <ArticleId IdType="pmc">PMC7178926</ArticleId>
            <ArticleId IdType="pubmed">32327746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011;50(3):552–562. doi: 10.1093/rheumatology/keq343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/keq343</ArticleId>
            <ArticleId IdType="pubmed">21078627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones G, Panova E. New insights and long-term safety of tocilizumab in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(10):195–199. doi: 10.1177/1759720X18798462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1759720X18798462</ArticleId>
            <ArticleId IdType="pmc">PMC6178374</ArticleId>
            <ArticleId IdType="pubmed">30327685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77(6):905–910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29592917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gron KL, Arkema EV, Glintborg B, Mehnert F, Ostergaard M, Dreyer L, et al.  Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Ann Rheum Dis. 2019;78(3):320–327. doi: 10.1136/annrheumdis-2018-214326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2018-214326</ArticleId>
            <ArticleId IdType="pubmed">30612115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tada Y, Sakai M, Nakao Y, Maruyama A, Ono N, Koarada S. Placental transfer of tocilizumab in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2019;58(9):1694–1695. doi: 10.1093/rheumatology/kez155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kez155</ArticleId>
            <ArticleId IdType="pubmed">31329987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoeltzenbein M, Beck E, Rajwanshi R, Gotestam SC, Berber E, Schaefer C, et al.  Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum. 2016;46(2):238–245. doi: 10.1016/j.semarthrit.2016.05.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2016.05.004</ArticleId>
            <ArticleId IdType="pubmed">27346577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakajima K, Watanabe O, Mochizuki M, Nakasone A, Ishizuka N, Murashima A. Pregnancy outcomes after exposure to tocilizumab: a retrospective analysis of 61 patients in Japan. Mod Rheumatol. 2016;26(5):667–671. doi: 10.3109/14397595.2016.1147405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/14397595.2016.1147405</ArticleId>
            <ArticleId IdType="pmc">PMC5020345</ArticleId>
            <ArticleId IdType="pubmed">26873562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al.  2020 American College of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529–556. doi: 10.1002/art.41191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.41191</ArticleId>
            <ArticleId IdType="pubmed">32090480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institute of health. Drugs and Lactation Database Eculizumab (July 2020). https://www.ncbi.nlm.nih.gov/books/NBK501921/. Accessed 24 Aug 2020</Citation>
        </Reference>
        <Reference>
          <Citation>Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, et al.  Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 2010;28(11):1203–1207. doi: 10.1038/nbt.1691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.1691</ArticleId>
            <ArticleId IdType="pubmed">20953198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125(Pt 7):1450–1461. doi: 10.1093/brain/awf151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awf151</ArticleId>
            <ArticleId IdType="pmc">PMC5444467</ArticleId>
            <ArticleId IdType="pubmed">12076996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soltys J, Liu Y, Ritchie A, Wemlinger S, Schaller K, Schumann H, et al.  Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica. J Clin Investig. 2019;129(5):2000–2013. doi: 10.1172/JCI122942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI122942</ArticleId>
            <ArticleId IdType="pmc">PMC6486354</ArticleId>
            <ArticleId IdType="pubmed">30958797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geis C, Ritter C, Ruschil C, Weishaupt A, Grunewald B, Stoll G, et al.  The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model. Exp Neurol. 2015;265:8–21. doi: 10.1016/j.expneurol.2014.12.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2014.12.015</ArticleId>
            <ArticleId IdType="pmc">PMC4382207</ArticleId>
            <ArticleId IdType="pubmed">25542977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett JL, Owens GP. Neuromyelitis optica: deciphering a complex immune-mediated astrocytopathy. J Neuroophthalmol. 2017;37(3):291–299. doi: 10.1097/WNO.0000000000000508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WNO.0000000000000508</ArticleId>
            <ArticleId IdType="pmc">PMC5557670</ArticleId>
            <ArticleId IdType="pubmed">28410278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schatz-Jakobsen JA, Zhang Y, Johnson K, Neill A, Sheridan D, Andersen GR. Structural basis for eculizumab-mediated inhibition of the complement terminal pathway. J Immunol. 2016;197(1):337–344. doi: 10.4049/jimmunol.1600280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1600280</ArticleId>
            <ArticleId IdType="pubmed">27194791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardo S, Giovannoni G, Hawkes C, Lechner-Scott J, Waubant E, Levy M. Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2019;33:A1–A2. doi: 10.1016/j.msard.2019.07.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2019.07.001</ArticleId>
            <ArticleId IdType="pubmed">31324299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al.  Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554–562. doi: 10.1016/S1474-4422(13)70076-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(13)70076-0</ArticleId>
            <ArticleId IdType="pubmed">23623397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Issa E, Salloum T, Tokajian S. From normal flora to brain abscesses: a review of Streptococcus intermedius. Front Microbiol. 2020;11:826. doi: 10.3389/fmicb.2020.00826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2020.00826</ArticleId>
            <ArticleId IdType="pmc">PMC7221147</ArticleId>
            <ArticleId IdType="pubmed">32457718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarno L, Tufano A, Maruotti GM, Martinelli P, Balletta MM, Russo D. Eculizumab in pregnancy: a narrative overview. J Nephrol. 2019;32(1):17–25. doi: 10.1007/s40620-018-0517-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40620-018-0517-z</ArticleId>
            <ArticleId IdType="pubmed">30159857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallstensen RF, Bergseth G, Foss S, Jaeger S, Gedde-Dahl T, Holt J, et al.  Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. 2015;220(4):452–459. doi: 10.1016/j.imbio.2014.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.imbio.2014.11.003</ArticleId>
            <ArticleId IdType="pubmed">25468724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly RJ, Hochsmann B, Szer J, Kulasekararaj A, de Guibert S, Roth A, et al.  Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032–1039. doi: 10.1056/NEJMoa1502950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1502950</ArticleId>
            <ArticleId IdType="pubmed">26352814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duineveld C, Wijnsma KL, Volokhina EB, van den Heuvel LPB, van de Kar NCAJ, Wetzels JFM. Placental passage of eculizumab and complement blockade in a newborn. Kidney Int. 2019;95(4):996. doi: 10.1016/j.kint.2019.01.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.kint.2019.01.012</ArticleId>
            <ArticleId IdType="pubmed">30904074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabatino JJ, Jr, Probstel AK, Zamvil SS. B cells in autoimmune and neurodegenerative central nervous system diseases. Nat Rev Neurosci. 2019;20(12):728–745. doi: 10.1038/s41583-019-0233-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41583-019-0233-2</ArticleId>
            <ArticleId IdType="pubmed">31712781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sellebjerg F, Blinkenberg M, Sorensen PS. Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis. CNS Drugs. 2020;34(3):269–280. doi: 10.1007/s40263-020-00704-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40263-020-00704-w</ArticleId>
            <ArticleId IdType="pubmed">31994023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, et al.  Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris) 2018;174(4):255–264. doi: 10.1016/j.neurol.2017.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurol.2017.11.005</ArticleId>
            <ArticleId IdType="pubmed">29606320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270–1272. doi: 10.1212/01.WNL.0000159399.81861.D5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000159399.81861.D5</ArticleId>
            <ArticleId IdType="pubmed">15824362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443–1448. doi: 10.1001/archneur.65.11.noc80069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.65.11.noc80069</ArticleId>
            <ArticleId IdType="pubmed">18779415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17(10):1225–1230. doi: 10.1177/1352458511404586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458511404586</ArticleId>
            <ArticleId IdType="pubmed">21622594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110–1117. doi: 10.1001/jamaneurol.2013.3071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2013.3071</ArticleId>
            <ArticleId IdType="pubmed">23897062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zephir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, et al.  Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015;262(10):2329–2335. doi: 10.1007/s00415-015-7852-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-015-7852-y</ArticleId>
            <ArticleId IdType="pubmed">26194198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nosadini M, Alper G, Riney CJ, Benson LA, Mohammad SS, Ramanathan S, et al.  Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016;3(1):e188. doi: 10.1212/NXI.0000000000000188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000188</ArticleId>
            <ArticleId IdType="pmc">PMC4723136</ArticleId>
            <ArticleId IdType="pubmed">26819962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang CS, Yang L, Li T, Zhang DQ, Jin WN, Li MS, et al.  Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology. 2013;81(8):710–713. doi: 10.1212/WNL.0b013e3182a1aac7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182a1aac7</ArticleId>
            <ArticleId IdType="pmc">PMC3776460</ArticleId>
            <ArticleId IdType="pubmed">23884041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412–1420. doi: 10.1001/archneurol.2011.154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2011.154</ArticleId>
            <ArticleId IdType="pubmed">21747007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, et al.  Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310–1315. doi: 10.1212/WNL.0b013e3182152881.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182152881</ArticleId>
            <ArticleId IdType="pubmed">21482945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radaelli M, Moiola L, Sangalli F, Esposito F, Barcella V, Ferre L, et al.  Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler. 2016;22(4):511–519. doi: 10.1177/1352458515594042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458515594042</ArticleId>
            <ArticleId IdType="pubmed">26199350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durozard P, Rico A, Boutiere C, Maarouf A, Lacroix R, Cointe S, et al.  Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol. 2020;87(2):256–266. doi: 10.1002/ana.25648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.25648</ArticleId>
            <ArticleId IdType="pubmed">31725931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trewin BP, Adelstein S, Spies JM, Beadnall HN, Barton J, Ho N, et al.  Precision therapy for neuromyelitis optica spectrum disorder: a retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. Mult Scler Relat Disord. 2020;43:102175. doi: 10.1016/j.msard.2020.102175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2020.102175</ArticleId>
            <ArticleId IdType="pubmed">32417664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, Gallagher S, Monson NL, Herbst R, Wang Y. Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med. 2016;5(12):107. doi: 10.3390/jcm5120107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm5120107</ArticleId>
            <ArticleId IdType="pmc">PMC5184780</ArticleId>
            <ArticleId IdType="pubmed">27886126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, et al.  Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016;18(1):131. doi: 10.1186/s13075-016-1021-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-016-1021-2</ArticleId>
            <ArticleId IdType="pmc">PMC4895815</ArticleId>
            <ArticleId IdType="pubmed">27267753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agius MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, Li J, Patra K, et al.  Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 2019;25(2):235–245. doi: 10.1177/1352458517740641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458517740641</ArticleId>
            <ArticleId IdType="pmc">PMC6360486</ArticleId>
            <ArticleId IdType="pubmed">29143550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. doi: 10.1155/2012/985646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2012/985646</ArticleId>
            <ArticleId IdType="pmc">PMC3251916</ArticleId>
            <ArticleId IdType="pubmed">22235228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, et al.  Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol. 2007;47(9):1119–1128. doi: 10.1177/0091270007305297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0091270007305297</ArticleId>
            <ArticleId IdType="pubmed">17766699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. J Am Soc Hematol. 2001;117(5):1499–1506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21098742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith JB, Hellwig K, Fink K, Lyell DJ, Piehl F, Langer-Gould A. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020 doi: 10.1212/NXI.0000000000000734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000734</ArticleId>
            <ArticleId IdType="pmc">PMC7217660</ArticleId>
            <ArticleId IdType="pubmed">32358226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, et al.  Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5(3):e453. doi: 10.1212/NXI.0000000000000453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000453</ArticleId>
            <ArticleId IdType="pmc">PMC5858951</ArticleId>
            <ArticleId IdType="pubmed">29564373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munger KC, Samkoff LM. Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy. Mult Scler Relat Disord. 2020;37:101442. doi: 10.1016/j.msard.2019.101442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2019.101442</ArticleId>
            <ArticleId IdType="pubmed">32173005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bragnes Y, Boshuizen R, de VA, Lexberg A, Ostensen M. Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology (Oxford) 2017;56(6):1047–1048. doi: 10.1093/rheumatology/kex039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kex039</ArticleId>
            <ArticleId IdType="pubmed">28339781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krysko KM, LaHue SC, Anderson A, Rutatangwa A, Rowles W, Schubert RD, et al.  Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions. Neurol Neuroimmunol Neuroinflamm. 2020 doi: 10.1212/NXI.0000000000000637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000637</ArticleId>
            <ArticleId IdType="pmc">PMC6857908</ArticleId>
            <ArticleId IdType="pubmed">31719115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institute of health. Rtuximab. Drugs and lactation Database (lactMed).https://www.ncbi.nlm.nih.gov/books/NBK501798/. Accessed 19 May 2020</Citation>
        </Reference>
        <Reference>
          <Citation>Silbermann E, Bourdette D. A new era for neuromyelitis optica spectrum disorder. Lancet. 2019;394(10206):1304–1305. doi: 10.1016/S0140-6736(19)31878-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(19)31878-1</ArticleId>
            <ArticleId IdType="pubmed">31495499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, et al.  Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry. 2017;88(8):639–647. doi: 10.1136/jnnp-2017-315603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2017-315603</ArticleId>
            <ArticleId IdType="pmc">PMC5537514</ArticleId>
            <ArticleId IdType="pubmed">28572277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salzer J, Svenningsson R, Alping P, Novakova L, Bjorck A, Fink K, et al.  Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016;87(20):2074–2081. doi: 10.1212/WNL.0000000000003331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000003331</ArticleId>
            <ArticleId IdType="pmc">PMC5109942</ArticleId>
            <ArticleId IdType="pubmed">27760868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, et al.  Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler. 2018;24(9):1224–1233. doi: 10.1177/1352458517720044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458517720044</ArticleId>
            <ArticleId IdType="pubmed">28762877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holmoy T, Fogdell-Hahn A, Svenningsson A. Serum sickness following rituximab therapy in multiple sclerosis. Neurol Clin Pract. 2019;9(6):519–521. doi: 10.1212/CPJ.0000000000000685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/CPJ.0000000000000685</ArticleId>
            <ArticleId IdType="pmc">PMC6927430</ArticleId>
            <ArticleId IdType="pubmed">32042497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, et al.  Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1078–1085. doi: 10.1136/annrheumdis-2016-210297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2016-210297</ArticleId>
            <ArticleId IdType="pubmed">28007755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frampton JE. Eculizumab: a review in neuromyelitis optica spectrum disorder. Drugs. 2020;80(7):719–727. doi: 10.1007/s40265-020-01297-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-020-01297-w</ArticleId>
            <ArticleId IdType="pmc">PMC7183484</ArticleId>
            <ArticleId IdType="pubmed">32266705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koelman DLH, Brouwer MC, van de Beek D. Targeting the complement system in bacterial meningitis. Brain. 2019;142(11):3325–3337. doi: 10.1093/brain/awz222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awz222</ArticleId>
            <ArticleId IdType="pmc">PMC6821383</ArticleId>
            <ArticleId IdType="pubmed">31373605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alashkar F, Vance C, Herich-Terhurne D, Preising N, Duhrsen U, Roth A. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab. Ann Hematol. 2017;96(4):589–596. doi: 10.1007/s00277-017-2924-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00277-017-2924-y</ArticleId>
            <ArticleId IdType="pubmed">28124080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al.  Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6619057</ArticleId>
            <ArticleId IdType="pubmed">30767274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al.  Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2019;77(2):184–191. doi: 10.1001/jamaneurol.2019.3365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2019.3365</ArticleId>
            <ArticleId IdType="pmc">PMC6784753</ArticleId>
            <ArticleId IdType="pubmed">31589278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al.  Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol. 2016;68(1):56–66. doi: 10.1002/art.39399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.39399</ArticleId>
            <ArticleId IdType="pubmed">26315675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mealy MA, Cook LJ, Pache F, Velez DL, Borisow N, Becker D, et al.  Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;23:78–82. doi: 10.1016/j.msard.2018.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2018.05.003</ArticleId>
            <ArticleId IdType="pubmed">29783157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nazi I, Kelton JG, Larche M, Snider DP, Heddle NM, Crowther MA, et al.  The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11):1946–1953. doi: 10.1182/blood-2013-04-494096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2013-04-494096</ArticleId>
            <ArticleId IdType="pmc">PMC3773242</ArticleId>
            <ArticleId IdType="pubmed">23851398</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
